Biblio

Author Title [ Type

] Year

Filters: Author is Morales, George [Clear All Filters]

Journal Article

Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, A Ayuk F, Aziz M, Baez J, Choe H, DeFilipp Z, et al. A validated risk stratification that incorporates MAGIC biomarkers predicts long term outcomes in pediatric patients with acute GVHD. Transplant Cell Ther. 2024.

Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, et al. Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2018.

Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.

Prado-Acosta M, Jeong S, Utrero-Rico A, Goncharov T, Webster JD, Holler E, Morales G, Dellepiane S, Levine JE, Rothenberg ME, et al. Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects. Sci Transl Med. 2023;15(727):eadf8366.

Zewde MGetachew, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, Chanswangphuwana C, Choe H, DeFilipp Z, et al. Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.

Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Malki MMAl, Ayuk F, Bader P, Baez J, et al. A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.